Ignite Creation Date:
2025-12-25 @ 4:08 AM
Ignite Modification Date:
2026-05-29 @ 4:17 PM
Study NCT ID:
NCT00428220
Status:
COMPLETED
Last Update Posted:
2019-06-27
First Post:
2007-01-26
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
Sponsor:
Pfizer
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Metastatic Breast Cancer | View |
| None | Advanced Breast Cancer | View |
| None | Metastatic Castration Resistant Prostate Cancer | View |
| None | Metastatic Renal Cell Cancer | View |
| None | Non-Small Cell Lung Cancer | View |
| None | Thyroid Cancer | View |
| None | Advanced/Metastatic Non-Small Cell Lung Cancer | View |
| None | Advanced Gastric Cancer | View |
| None | Gastrointestinal Stromal Tumor | View |
| None | Hepatocellular Carcinoma | View |
| None | Pancreatic Islet Cell Carcinoma | View |
| None | Pancreatic Neuroendocrine Tumor | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Potentially other tumor types in the future | View |